MUDr. Peter Múdry, Ph.D.
odborný asistent – Klinika dětské onkologie
korespondenční adresa:
Černopolní 212/9, 662 63 Brno
telefon: | 532 23 4126, 4614 |
---|---|
e‑mail: |
Počet publikací: 146
2024
-
Localized incompletely resected standard risk rhabdomyosarcoma in children and adolescents: Results from the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 trial
Cancer, rok: 2024, DOI
-
Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients
International journal of cancer, rok: 2024, ročník: 155, vydání: 8, DOI
-
Precision immuno-oncology approach for four malignant tumors in siblings with constitutional mismatch repair deficiency syndrome
NPJ PRECISION ONCOLOGY, rok: 2024, ročník: 8, vydání: 1, DOI
2023
-
Comprehensive genomic profiling and individual therapeutic planning in high-risk/refractory pediatric solid tumors: A single-center real-world study.
Rok: 2023, druh: Konferenční abstrakty
-
Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study
Journal of clinical oncology, rok: 2023, ročník: 41, vydání: 13, DOI
-
Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone
Cancers, rok: 2023, ročník: 15, vydání: 18, DOI
-
Risk factors for tumors or leukemia development in the first two years of life
Biomedical Papers, Olomouc: Palacky University, rok: 2023, ročník: 167, vydání: 2, DOI
-
Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity
Scientific reports, rok: 2023, ročník: 13, vydání: 1, DOI
2022
-
A case report of aneurysmal bone cyst of the proximal ulna treated with allograft resection after neoadjuvant targeted therapy
Rok: 2022, druh: Konferenční abstrakty
-
Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing
JCO PRECISION ONCOLOGY, rok: 2022, ročník: 6, vydání: June 2022, DOI